Indication & Safety Information for LEUKERAN®
Patients should never be allowed to take LEUKERAN® without medical supervision and should consult their physician if they experience skin rash, bleeding, fever, jaundice, persistent cough, seizures, nausea, vomiting, amenorrhea, or unusual lumps/masses. Women of childbearing potential should be advised to avoid becoming pregnant.
WARNING:
LEUKERAN® (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility. See full warnings and precautions
INDICATIONS AND USAGE
LEUKERAN® (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.
CONTRAINDICATIONS
Chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. Patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. There may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
WARNING:
LEUKERAN® (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility. See full warnings and precautions
Indication & Safety Information for LEUKERAN®
Patients should never be allowed to take LEUKERAN® without medical supervision and should consult their physician if they experience skin rash, bleeding, fever, jaundice, persistent cough, seizures, nausea, vomiting, amenorrhea, or unusual lumps/masses. Women of childbearing potential should be advised to avoid becoming pregnant.
INDICATIONS AND USAGE
LEUKERAN® (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.
CONTRAINDICATIONS
Chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. Patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. There may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.
SIDE EFFECTS
Common side effects:
- nausea
- vomiting
- diarrhea
- tremors or shaking
- numbness,
- burning, pain, and
- tingling feeling
Serious side effects:
Contact your doctor if you experience any of the following:
seizures (convulsions); fever, chills, body aches, flu symptoms, sores in your mouth and throat, pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating; easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; sore throat, and headache with a severe blistering, peeling, and red skin rash; itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); an unusual mass or lump; chest discomfort, dry cough or hack, persistent cough; shortness of breath on exertion; weakness or tiredness, rapid weight loss; severe nausea, vomiting, or diarrhea; or missed menstrual periods.
ADVERSE REACTIONS
To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.